CMS Rule that Will Set 340B Hospitals’ Part B Drug Reimbursement for 2022 Moves Closer to Release

The CMS final rule that will set Medicare reimbursement in 2022 to 340B hospitals for physician-administered drugs is another step closer to release.

The U.S. Centers for Medicare & Medicaid Services (CMS) final rule that will set what Medicare will pay 340B hospitals for physician-administered drugs next year is another step closer to release.

CMS last week Thursday sent its calendar year

Read More »

In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies

HRSA confirmed yesterday that 340B program administrative dispute resolution (ADR) panels have been assigned.

The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by

Read More »

Boehringer Ingelheim Defends its 340B Contract Pharmacy Policy After HRSA Finds it Is Unlawful

Boehringer Ingelheim disputes HRSA's Oct. 4 finding that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

“Boehringer Ingelheim Pharmaceuticals, Inc. is committed to ensuring that its

Read More »

Final 340B Registration Period of 2021 Ends on Oct. 15

The final 340B covered entity registration period of 2021 ends on Friday, Oct. 15.

The final 340B covered entity registration period of the year began on Friday, Oct. 1 and ends on Friday, Oct. 15. Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during the period can begin participating

Read More »

Breaking News

Breaking: HRSA Tells Boehringer Ingelheim its 340B Contract Pharmacy Restrictions Are Illegal

HRSA informed Boehringer Ingelheim today that its restrictions on 340B pricing when hospitals use contract pharmacies are illegal.

A senior federal health official informed drug manufacturer Boehringer Ingelheim (BI) today its restrictions on 340B pricing when hospitals use contract pharmacies are illegal and must end immediately, or BI could face civil monetary penalties.

U.S. Health Resources and Services

Read More »

It’s Official: Biden Administration Rescinds Trump’s 340B Insulin/EpiPen Final Rule

The Biden administration announced this morning it is rescinding the Trump administration’s regulatory requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income patients with high-cost or no health insurance.

The Biden administration this morning, as widely expected, announced it is rescinding the Trump administration’s regulatory requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income patients with high-cost or no health

Read More »

Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic

HRSA says it may resume some onsite audits of 340B covered entities as early as next month, sparking concerns among some providers already battling the fallout from the Delta variant of COVID-19.

The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October. This is sparking concern among 340B providers in light of crisis conditions in some states fueled

Read More »

Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action

Hospital trade groups have lodged strong objections to CMS's proposal to maintain deep Medicare Part B reimbursement cuts, while PhRMA is suggesting even further 340B reforms.

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B drug reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand

Read More »

Breaking News

Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts

HRSA has referred six drug manufacturers to the HHS Office of Inspector General for refusing to offer 340B discounts in the contract pharmacy setting.

The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered

Read More »

Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule

Former President Trump signed an executive order in July 2020 directing HHS to limit what 340B health centers can charge patients for insulin and EpiPen-type devices.

The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.

Late last week Thursday, the U.S. Health Resources

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live